Literature DB >> 12554733

Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor.

Yutaka Hasegawa1, James R Erickson, Graham J Goddard, Shuangxing Yu, Shuying Liu, Kwai Wa Cheng, Astrid Eder, Koji Bandoh, Junken Aoki, Renata Jarosz, Andrew D Schrier, Kevin R Lynch, Gordon B Mills, Xianjun Fang.   

Abstract

Lysophosphatidic acid (LPA) is a bioactive lysophospholipid mediator that acts through G protein-coupled receptors. Most cell lines in culture express one or more LPA receptors, making it difficult to assign a response to specific LPA receptors. Dissection of the signaling properties of LPA has been hampered by lack of LPA receptor subtype-specific agonists and antagonists. The present study characterizes an ester-linked thiophosphate derivative (1-oleoyl-2-O-methyl-rac-glycerophosphothionate, OMPT) of LPA. OMPT is a functional LPA analogue with potent mitogenic activity in fibroblasts. In contrast to LPA, OMPT does not couple to the pheromone response through the LPA(1) receptor in yeast cells. OMPT induces intracellular calcium increases efficiently in LPA(3) receptor-expressing Sf9 cells but poorly in LPA(2) receptor-expressing cells. Guanosine 5'-O-(3-[(35)S]thio)triphosphate binding assays in mammalian cells showed that LPA exhibits agonistic activity on all three LPA receptor subtypes, whereas OMPT has a potent agonistic effect only on the LPA(3) receptor. In transiently transfected HEK293 cells, OMPT stimulates mitogen-activated protein kinases through the LPA(3) but not the LPA(1) or LPA(2) receptors. Furthermore, OMPT-induced intracellular calcium mobilization in mammalian cells is efficiently inhibited by the LPA(1)/LPA(3) receptor-selective antagonist VPC12249. These results establish that OMPT is an LPA(3)-selective agonist. OMPT binding to the LPA(3) receptor in mammalian cells is sufficient to elicit multiple responses, including activation of G proteins, calcium mobilization, and activation of mitogen-activated protein kinases. Thus OMPT offers a powerful probe for the dissection of LPA signaling events in complex mammalian systems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554733     DOI: 10.1074/jbc.M209168200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

Review 1.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 2.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

4.  Regulation of cell survival by lipid phosphate phosphatases involves the modulation of intracellular phosphatidic acid and sphingosine 1-phosphate pools.

Authors:  Jaclyn Long; Peter Darroch; Kah Fei Wan; Kok Choi Kong; Nicholas Ktistakis; Nigel J Pyne; Susan Pyne
Journal:  Biochem J       Date:  2005-10-01       Impact factor: 3.857

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.

Authors:  James E East; Karen M Carter; Perry C Kennedy; Nancy A Schulte; Myron L Toews; Kevin R Lynch; Timothy L Macdonald
Journal:  Medchemcomm       Date:  2011-03-03       Impact factor: 3.597

7.  Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid.

Authors:  Joanna Gajewiak; Ryoko Tsukahara; Yuko Fujiwara; Gabor Tigyi; Glenn D Prestwich
Journal:  Org Lett       Date:  2008-02-20       Impact factor: 6.005

8.  Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.

Authors:  Molly K Altman; Vashisht Gopal; Wei Jia; Shuangxing Yu; Hassan Hall; Gordon B Mills; A Cary McGinnis; Michael G Bartlett; Guowei Jiang; Damian Madan; Glenn D Prestwich; Yong Xu; Michael A Davies; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-06-09       Impact factor: 27.401

9.  Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells.

Authors:  Yutaka Hasegawa; Mandi Murph; Shuangxing Yu; Gabor Tigyi; Gordon B Mills
Journal:  Mol Oncol       Date:  2008-06       Impact factor: 6.603

10.  The role of lysophosphatidic acid receptors in phenotypic modulation of vascular smooth muscle cells.

Authors:  Zhibin Zhou; Jianping Niu; Zhijun Zhang
Journal:  Mol Biol Rep       Date:  2009-09-16       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.